Carbon reduction plan

Supplier name: AstraZeneca PLC

Publication date: May 2026

Commitment to achieving net zero

Through Ambition Zero Carbon, AstraZeneca continues to invest in reducing GHG emissions across the research, development, manufacture and supply of its medicines. AstraZeneca remains on track to reduce Scope 1 and 2 greenhouse gas (GHG) emissions from global operations by 98% by 2026 from a 2015 baseline, aiming to reduce the entire value chain footprint by 35% by 2030 from a 2019 baseline, supporting a path to net zero.

We are pursuing ambitious science-based decarbonisation targets, accelerating our progress towards net zero, and managing the risks and opportunities presented by climate change:

- We recognise the importance of our supply chain and suppliers, whom we engage with, educate, support and incentivise to act
- We partner with our sector peers, including at a high-level through the Sustainable Markets Initiative Health Systems Task Force
- We are transparent about our performance, methodologies, transition plan and assessment of climate-related risks and opportunities presented by a low-carbon economy and net-zero healthcare
- We focus on delivering absolute reductions in all our direct and indirect GHG emissions sources across the value chain – Scopes 1, 2 and 3.
- We aim to maximise the transition from air freight to sea freight and implement new strategies for business travel to reduce emissions.
- We embed sustainable science in R&D from the beginning of drug discovery, for example through embracing Green Chemistry principles.

Baseline emissions footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2015 for Scope 1 & 2, 2019 for Scope 3	
Additional details relating to the baseline emissions calculations	
AstraZeneca reports greenhouse gas (GHG) emissions in accordance with the World Resource Institute / World Business Council for Sustainable Development (WRI/WBCSD) Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard, Revised Edition (2015) and Corporate Value Chain (Scope 3), Accounting and Reporting Standard (2011). This data is reported at the global enterprise level and therefore data in this CRP submission will utilise this data. AstraZeneca Scope 1 & 2 performance is tracked relative to a 2015 baseline year. Scope 3 performance is tracked relative to a 2019 baseline year. The baseline years are representative of normal operating conditions and the difference in baseline years between emission scopes is due to availability of data. Emissions are reported on a calendar year basis (1 January – 31 December). Recalculations to baseline GHG data occurs to ensure that real changes to emissions are captured rather than a result of AstraZeneca structural (acquisitions, divestments, mergers) or methodology changes (error correction or calculation adjustments). This enables consistency to be maintained over time. Recalculation will be considered dependent upon significance to GHG emissions with updates disclosed. An internal procedure sets out the thresholds and process for recalculation and that adjustments are logged and communicated to our assurance partners as part of annual reporting.	
Baseline year emissions: 2015 & 2019	
EMISSIONS	**TOTAL (tCO_2e)**
Scope 1	298,498 (2015)
Scope 2	322,319 (2015) (Market Based)
Scope 3 (Included Sources)	5,025,169 (2019)
Total Emissions	N/A

Current emissions reporting

Reporting Year: 2025	
EMISSIONS	**TOTAL (tCO_2e)**
Scope 1	62,587
Scope 2	11,316 (Market Based)
Scope 3 (Gross emissions – all relevant categories)	6,197,690
Total Emissions	6,271,593

Emissions reduction targets

We aim to reduce our impact on the planet and help restore our natural world. Our Sustainability targets to 2030:

- 35% reduction in Scope 3*
- >100m trees planted through AZ Forest
- 3x energy productivity
- 50% waste circularity rate
- Water stewardship strategies delivered at key sites

*vs 2019 baseline. NB Scope 1 & 2 target: By 2026 reduce emissions by 98% vs 2015.

Carbon reduction projects

Completed carbon reduction initiatives

As of the end of 2025, our gross market-based Scope 1 and 2 greenhouse gas emissions are 73,903 tCO2e, an 88% reduction from the 2015 baseline of 620,818 tCO2e (a reduction of 546,915 tCO2e). Contributing factors include large-scale energy efficiency across sites, expansion of certified renewable electricity to 94% of on-site consumption (RE100-aligned), onsite solar generation, electrification of our road fleet (81.5% Battery Electric Vehicles), and the commencement of biomethane supply agreements in the US and UK. These measures are already in effect and will remain in effect during contract performance.

We met multiple targets scheduled to conclude in 2025. We launched a next-generation propellant inhaler in the UK after approval by the UK Medicines and Healthcare products Regulatory Agency. We exceeded a planned 10% reduction in total site energy consumption versus 2015 resulting in a 20% reduction in 2025. In parallel, we more than doubled energy productivity from the 2015 baseline. We had a 23% reduction in water use and waste generated since 2015. Finally, we raised the share of primary activity data in Scope 3 reporting to 69%, improving traceability and enabling more accurate measurement against our value-chain decarbonisation plans.

We are investing $400 million in the AZ Forest programme worldwide to restore nature, benefit local communities and compensate for residual emissions. In collaboration with Forestry England, we achieved the 1 million trees milestone in 2025.

Engaging with suppliers is key to encouraging the adoption of science-based targets and scaling sustainable solutions. This engagement has resulted in over 80% of our eligible supplier spend now being with partners that have set their own science-based targets.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard[i] and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.[ii]

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.[iii]

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the supplier:

James Woodhouse, Head of Corporate Affairs, UK

Date: 10th May 2026

GB-76190 Date of prep: May 2026

i https://ghgprotocol.org/corporate-standard
ii https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting
iiihttps://ghgprotocol.org/standards/scope-3-standard